Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities

Abstract

Copper, one of the essential nutrients for the human body, acts as an electron relay in multiple pathways due to its redox properties. Both deficiencies and excesses of copper lead to cellular fragility. Therefore, it can manifest pro- and anti-cancer properties in tumors. Therefore, it is crucial to clarify the copper activity within the cell. We have thoughtfully summarized the metabolic activities of copper from a macro and micro perspective. Cuproptosis, as well as other forms of cell death, is directly or indirectly interfered with by Cu²⁺, causing cancer cell death. Meanwhile, we did pan-cancer analysis of cuproptosis-related genes to further clarify the roles of these genes. In addition, copper has been found to be involved in multiple pathways within the metastasis of cancer cells. Given the complexity of copper's role, we are compelled to ask: is copper a friend or a foe? Up to now, copper has been used in various clinical applications, including protocols for measurement of copper concentration and bioimaging of radioactive ⁶⁴Cu. But therapeutically it is still a continuation of the old medicine, and new possibilities need to be explored, such as the use of nanomaterials. Some studies have also shown that copper has considerable interventional power in metabolic cancers, which provides the great applications potential of copper therapy in specific cancer types. This paper reviews the dual roles played by cuproptosis in cancer from the new perspectives of oxidative stress, cell death, and tumor metastasis, and points out the value of its application in specific cancer types, summarizes the value of its testing and imaging from the perspective of clinical application as well as the current feasible options for the new use of the old drugs, and emphasizes the prospects for the application of nano-copper.

Keywords

cancer therapy / copper metabolism / cuproplasia / cuproptosis / intracellular copper-associated pathway

References

[1] Chambers A, Krewski D, Birkett N, Plunkett L, Hertzberg R, Danzeisen R, et al. An exposure-response curve for copper excess and deficiency. J Toxicol Environ Health B Crit Rev. 2010; 13(7-8): 546–78.

[2] Saroli Palumbo C, Schilsky ML. Clinical practice guidelines in Wilson disease. Ann Transl Med. 2019; 7(Suppl 2): S65.

[3] Eisses JF, Chi Y, Kaplan JH. Stable plasma membrane levels of hCTR1 mediate cellular copper uptake. J Biol Chem. 2005; 280(10): 9635–9.

[4] Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006; 108(4): 1388–94.

[5] Wyman S, Simpson RJ, McKie AT, Sharp PA. Dcytb (Cybrd1) functions as both a ferric and a cupric reductase in vitro. FEBS Lett. 2008; 582(13): 1901–6.

[6] Harris ED. Copper as a cofactor and regulator of copper,zinc superoxide dismutase. J Nutr. 1992; 122(3 Suppl): 636–40.

[7] Polishchuk EV, Concilli M, Iacobacci S, Chesi G, Pastore N, Piccolo P, et al. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Dev Cell. 2014; 29(6): 686–700.

[8] Roelofsen H, Wolters H, Van Luyn MJ, Miura N, Kuipers F, Vonk RJ. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion. Gastroenterology. 2000; 119(3): 782–93.

[9] Turnlund JR. Human whole-body copper metabolism. Am J Clin Nutr. 1998; 67(5 Suppl): 960s–4s.

[10] Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022; 22(2): 102–13.

[11] Michniewicz F, Saletta F, Rouaen JRC, Hewavisenti RV, Mercatelli D, Cirillo G, et al. Copper: An Intracellular Achilles' Heel Allowing the Targeting of Epigenetics, Kinase Pathways, and Cell Metabolism in Cancer Therapeutics. ChemMedChem. 2021; 16(15): 2315–29.

[12] Liu WQ, Lin WR, Yan L, Xu WH, Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy. Immunol Rev. 2024; 321(1): 211–27.

[13] Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther. 2022; 7(1): 378.

[14] Xue Q, Kang R, Klionsky DJ, Tang D, Liu J, Chen X. Copper metabolism in cell death and autophagy. Autophagy. 2023; 19(8): 2175–95.

[15] Lee J, Peña MM, Nose Y, Thiele DJ. Biochemical characterization of the human copper transporter Ctr1. J Biol Chem. 2002; 277(6): 4380–7.

[16] Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997; 388(6641): 482–8.

[17] Kaplan JH, Maryon EB. How Mammalian Cells Acquire Copper: An Essential but Potentially Toxic Metal. Biophys J. 2016; 110(1): 7–13.

[18] Eisses JF, Kaplan JH. Molecular characterization of hCTR1, the human copper uptake protein. J Biol Chem. 2002; 277(32): 29162–71.

[19] Puig S, Lee J, Lau M, Thiele DJ. Biochemical and genetic analyses of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. J Biol Chem. 2002; 277(29): 26021–30.

[20] Maryon EB, Molloy SA, Ivy K, Yu H, Kaplan JH. Rate and regulation of copper transport by human copper transporter 1 (hCTR1). J Biol Chem. 2013; 288(25): 18035–46.

[21] Arredondo M, Muñoz P, Mura CV, Nùñez MT. DMT1, a physiologically relevant apical Cu1+ transporter of intestinal cells. Am J Physiol Cell Physiol. 2003; 284(6): C1525–30.

[22] Zimnicka AM, Ivy K, Kaplan JH. Acquisition of dietary copper: a role for anion transporters in intestinal apical copper uptake. Am J Physiol Cell Physiol. 2011; 300(3): C588–99.

[23] Li Y, Ma J, Wang R, Luo Y, Zheng S, Wang X. Zinc transporter 1 functions in copper uptake and cuproptosis. Cell Metab. 2024; 36(9): 2118–29.e6.

[24] Lichten LA, Cousins RJ. Mammalian zinc transporters: nutritional and physiologic regulation. Annu Rev Nutr. 2009; 29: 153–76.

[25] Stiles LI, Ferrao K, Mehta KJ. Role of zinc in health and disease. Clin Exp Med. 2024; 24(1): 38.

[26] Huang D, Chen L, Ji Q, Xiang Y, Zhou Q, Chen K, et al. Lead aggravates Alzheimer's disease pathology via mitochondrial copper accumulation regulated by COX17. Redox Biol. 2024; 69: 102990.

[27] Ramchandani D, Berisa M, Tavarez DA, Li Z, Miele M, Bai Y, et al. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. Nat Commun. 2021; 12(1): 7311.

[28] Petzoldt S, Kahra D, Kovermann M, Dingeldein AP, Niemiec MS, Ådén J, et al. Human cytoplasmic copper chaperones Atox1 and CCS exchange copper ions in vitro. Biometals. 2015; 28(3): 577–85.

[29] Cousins RJ. Metallothionein–aspects related to copper and zinc metabolism. J Inherit Metab Dis. 1983; 6(Suppl 1): 15–21.

[30] Lu S, Li Y, Yu Y. Glutathione-Scavenging Celastrol-Cu Nanoparticles Induce Self-Amplified Cuproptosis for Augmented Cancer Immunotherapy. Adv Mater. 2024; 36(35): e2404971.

[31] Beers J, Glerum DM, Tzagoloff A. Purification, characterization, and localization of yeast Cox17p, a mitochondrial copper shuttle. J Biol Chem. 1997; 272(52): 33191–6.

[32] Cobine PA, Pierrel F, Winge DR. Copper trafficking to the mitochondrion and assembly of copper metalloenzymes. Biochim Biophys Acta. 2006; 1763(7): 759–72.

[33] Chen J, Jiang Y, Shi H, Peng Y, Fan X, Li C. The molecular mechanisms of copper metabolism and its roles in human diseases. Pflugers Arch. 2020; 472(10): 1415–29.

[34] Timón-Gómez A, Nývltová E, Abriata LA, Vila AJ, Hosler J, Barrientos A. Mitochondrial cytochrome c oxidase biogenesis: Recent developments. Semin Cell Dev Biol. 2018; 76: 163–78.

[35] Glerum DM, Shtanko A, Tzagoloff A. Characterization of COX17, a yeast gene involved in copper metabolism and assembly of cytochrome oxidase. J Biol Chem. 1996; 271(24): 14504–9.

[36] Buchwald P, Krummeck G, Rödel G. Immunological identification of yeast SCO1 protein as a component of the inner mitochondrial membrane. Mol Gen Genet. 1991; 229(3): 413–20.

[37] Glerum DM, Shtanko A, Tzagoloff A. SCO1 and SCO2 act as high copy suppressors of a mitochondrial copper recruitment defect in Saccharomyces cerevisiae. J Biol Chem. 1996; 271(34): 20531–5.

[38] Chojnacka M, Gornicka A, Oeljeklaus S, Warscheid B, Chacinska A. Cox17 Protein Is an Auxiliary Factor Involved in the Control of the Mitochondrial Contact Site and Cristae Organizing System. J Biol Chem. 2015; 290(24): 15304–12.

[39] Wong PC, Waggoner D, Subramaniam JR, Tessarollo L, Bartnikas TB, Culotta VC, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci U S A. 2000; 97(6): 2886–91.

[40] Feng W, Ye F, Xue W, Zhou Z, Kang YJ. Copper regulation of hypoxia-inducible factor-1 activity. Mol Pharmacol. 2009; 75(1): 174–82.

[41] Skopp A, Boyd SD, Ullrich MS, Liu L, Winkler DD. Copper-zinc superoxide dismutase (Sod1) activation terminates interaction between its copper chaperone (Ccs) and the cytosolic metal-binding domain of the copper importer Ctr1. Biometals. 2019; 32(4): 695–705.

[42] Puig S, Thiele DJ. Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol. 2002; 6(2): 171–80.

[43] Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 2005; 24(3): 367–80.

[44] Matzuk MM, Dionne L, Guo Q, Kumar TR, Lebovitz RM. Ovarian function in superoxide dismutase 1 and 2 knockout mice. Endocrinology. 1998; 139(9): 4008–11.

[45] Gralla EB, Valentine JS. Null mutants of Saccharomyces cerevisiae Cu,Zn superoxide dismutase: characterization and spontaneous mutation rates. J Bacteriol. 1991; 173(18): 5918–20.

[46] Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC. A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J Biol Chem. 2001; 276(41): 38084–9.

[47] Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem. 2001; 276(42): 38388–93.

[48] Portnoy ME, Rosenzweig AC, Rae T, Huffman DL, O'Halloran TV, Culotta VC. Structure-function analyses of the ATX1 metallochaperone. J Biol Chem. 1999; 274(21): 15041–5.

[49] Hung IH, Casareno RL, Labesse G, Mathews FS, Gitlin JD. HAH1 is a copper-binding protein with distinct amino acid residues mediating copper homeostasis and antioxidant defense. J Biol Chem. 1998; 273(3): 1749–54.

[50] Itoh S, Kim HW, Nakagawa O, Ozumi K, Lessner SM, Aoki H, et al. Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem. 2008; 283(14): 9157–67.

[51] Banci L, Bertini I, Ciofi-Baffoni S, Huffman DL, O'Halloran TV. Solution structure of the yeast copper transporter domain Ccc2a in the apo and Cu(I)-loaded states. J Biol Chem. 2001; 276(11): 8415–26.

[52] Gitschier J, Moffat B, Reilly D, Wood WI, Fairbrother WJ. Solution structure of the fourth metal-binding domain from the Menkes copper-transporting ATPase. Nat Struct Biol. 1998; 5(1): 47–54.

[53] Lutsenko S, Petrukhin K, Cooper MJ, Gilliam CT, Kaplan JH. N-terminal domains of human copper-transporting adenosine triphosphatases (the Wilson's and Menkes disease proteins) bind copper selectively in vivo and in vitro with stoichiometry of one copper per metal-binding repeat. J Biol Chem. 1997; 272(30): 18939–44.

[54] DiDonato M, Narindrasorasak S, Forbes JR, Cox DW, Sarkar B. Expression, purification, and metal binding properties of the N-terminal domain from the wilson disease putative copper-transporting ATPase (ATP7B). J Biol Chem. 1997; 272(52): 33279–82.

[55] Arnesano F, Banci L, Bertini I, Bonvin AM. A docking approach to the study of copper trafficking proteins; interaction between metallochaperones and soluble domains of copper ATPases. Structure. 2004; 12(4): 669–76.

[56] Calvo J, Jung H, Meloni G. Copper metallothioneins. IUBMB Life. 2017; 69(4): 236–45.

[57] Bhattacharjee A, Chakraborty K, Shukla A. Cellular copper homeostasis: current concepts on its interplay with glutathione homeostasis and its implication in physiology and human diseases. Metallomics. 2017; 9(10): 1376–88.

[58] Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009; 30(1-2): 42–59.

[59] Hwang C, Sinskey AJ, Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. Science. 1992; 257(5076): 1496–502.

[60] Meredith MJ, Reed DJ. Status of the mitochondrial pool of glutathione in the isolated hepatocyte. J Biol Chem. 1982; 257(7): 3747–53.

[61] Horn N, Wittung-Stafshede P. ATP7A-Regulated Enzyme Metalation and Trafficking in the Menkes Disease Puzzle. Biomedicines. 2021; 9(4): 391.

[62] Fieten H, Gill Y, Martin AJ, Concilli M, Dirksen K, van Steenbeek FG, et al. The Menkes and Wilson disease genes counteract in copper toxicosis in Labrador retrievers: a new canine model for copper-metabolism disorders. Dis Model Mech. 2016; 9(1): 25–38.

[63] Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015; 14(1): 103–13.

[64] Kaler SG. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol. 2011; 7(1): 15–29.

[65] Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and regulation of human copper-transporting ATPases. Physiol Rev. 2007; 87(3): 1011–46.

[66] Petris MJ, Mercer JF, Culvenor JG, Lockhart P, Gleeson PA, Camakaris J. Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. Embo j. 1996; 15(22): 6084–95.

[67] Petris MJ, Camakaris J, Greenough M, LaFontaine S, Mercer JF. A C-terminal di-leucine is required for localization of the Menkes protein in the trans-Golgi network. Hum Mol Genet. 1998; 7(13): 2063–71.

[68] Petris MJ, Mercer JF. The Menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Hum Mol Genet. 1999; 8(11): 2107–15.

[69] Aubert L, Nandagopal N, Steinhart Z, Lavoie G, Nourreddine S, Berman J, et al. Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer. Nat Commun. 2020; 11(1): 3701.

[70] Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019; 25: 101084.

[71] Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol. 2011; 7(8): 504–11.

[72] Liochev SI. Reactive oxygen species and the free radical theory of aging. Free Radic Biol Med. 2013; 60: 1–4.

[73] Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2): 85–95.

[74] Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12(12): 931–47.

[75] Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016; 7(6): e2253.

[76] Lin Y, Jiang M, Chen W, Zhao T, Wei Y. Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed Pharmacother. 2019; 118: 109249.

[77] Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018; 41: 1–25.

[78] Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011; 283(2-3): 65–87.

[79] Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006; 160(1): 1–40.

[80] Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018; 80: 50–64.

[81] Griess B, Tom E, Domann F, Teoh-Fitzgerald M. Extracellular superoxide dismutase and its role in cancer. Free Radic Biol Med. 2017; 112: 464–79.

[82] Robbins D, Zhao Y. Manganese superoxide dismutase in cancer prevention. Antioxid Redox Signal. 2014; 20(10): 1628–45.

[83] Marklund SL, Holme E, Hellner L. Superoxide dismutase in extracellular fluids. Clin Chim Acta. 1982; 126(1): 41–51.

[84] Yang F, Pei R, Zhang Z, Liao J, Yu W, Qiao N, et al. Copper induces oxidative stress and apoptosis through mitochondria-mediated pathway in chicken hepatocytes. Toxicol In Vitro. 2019; 54: 310–6.

[85] Papa L, Manfredi G, Germain D. SOD1, an unexpected novel target for cancer therapy. Genes Cancer. 2014; 5(1-2): 15–21.

[86] Papa L, Hahn M, Marsh EL, Evans BS, Germain D. SOD2 to SOD1 switch in breast cancer. J Biol Chem. 2014; 289(9): 5412–6.

[87] Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med. 2009; 47(4): 344–56.

[88] Bourens M, Fontanesi F, Soto IC, Liu J, Barrientos A. Redox and reactive oxygen species regulation of mitochondrial cytochrome C oxidase biogenesis. Antioxid Redox Signal. 2013; 19(16): 1940–52.

[89] Ding Y, Chen Y, Wu Z, Yang N, Rana K, Meng X, et al. SsCox17, a copper chaperone, is required for pathogenic process and oxidative stress tolerance of Sclerotinia sclerotiorum. Plant Sci. 2022; 322: 111345.

[90] Lin SJ, Culotta VC. The ATX1 gene of Saccharomyces cerevisiae encodes a small metal homeostasis factor that protects cells against reactive oxygen toxicity. Proc Natl Acad Sci U S A. 1995; 92(9): 3784–8.

[91] Hatori Y, Yan Y, Schmidt K, Furukawa E, Hasan NM, Yang N, et al. Neuronal differentiation is associated with a redox-regulated increase of copper flow to the secretory pathway. Nat Commun. 2016; 7: 10640.

[92] Hatori Y, Clasen S, Hasan NM, Barry AN, Lutsenko S. Functional partnership of the copper export machinery and glutathione balance in human cells. J Biol Chem. 2012; 287(32): 26678–87.

[93] Hatori Y, Lutsenko S. An expanding range of functions for the copper chaperone/antioxidant protein Atox1. Antioxid Redox Signal. 2013; 19(9): 945–57.

[94] Hatori Y, Inouye S, Akagi R. Thiol-based copper handling by the copper chaperone Atox1. IUBMB Life. 2017; 69(4): 246–54.

[95] Freedman JH, Ciriolo MR, Peisach J. The role of glutathione in copper metabolism and toxicity. J Biol Chem. 1989; 264(10): 5598–605.

[96] Arteel GE, Sies H. The biochemistry of selenium and the glutathione system. Environ Toxicol Pharmacol. 2001; 10(4): 153–8.

[97] Ebrahimi SO, Reiisi S, Shareef S. miRNAs, oxidative stress, and cancer: A comprehensive and updated review. J Cell Physiol. 2020; 235(11): 8812–25.

[98] Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, et al. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A. 2011; 108(39): 16375–80.

[99] Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002; 94(4): 252–66.

[100] Hasselbalch HC, Thomassen M, Riley CH, Kjær L, Larsen TS, Jensen MK, et al. Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One. 2014; 9(11): e112786.

[101] Chen L, Li N, Zhang M, Sun M, Bian J, Yang B, et al. APEX2-based Proximity Labeling of Atox1 Identifies CRIP2 as a Nuclear Copper-binding Protein that Regulates Autophagy Activation. Angew Chem Int Ed Engl. 2021; 60(48): 25346–55.

[102] Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A. 2015; 112(33): E4600–9.

[103] Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 1984; 219(1): 1–14.

[104] Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death Cell. 2024; 187(2): 235–56.

[105] Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022; 15(1): 174.

[106] Cen D, Brayton D, Shahandeh B, Meyskens FL,., Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004; 47(27): 6914–20.

[107] Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006; 66(21): 10425–33.

[108] Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang CY, Zhang M, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008; 7(8): 2319–27.

[109] Hasinoff BB, Wu X, Yadav AA, Patel D, Zhang H, Wang DS, et al. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochem Pharmacol. 2015; 93(3): 266–76.

[110] Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019; 15(7): 681–9.

[111] Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022; 375(6586): 1254–61.

[112] Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, et al. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011; 104(10): 1564–74.

[113] Shimada K, Reznik E, Stokes ME, Krishnamoorthy L, Bos PH, Song Y, et al. Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells. Cell Chem Biol. 2018; 25(5): 585–94.e7.

[114] Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019; 366(6467): 818–22.

[115] Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020; 43(11): 1144–61.

[116] Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017; 552(7684): 194–9.

[117] Skrott Z, Majera D, Gursky J, Buchtova T, Hajduch M, Mistrik M, et al. Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase. Oncogene. 2019; 38(40): 6711–22.

[118] Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W. Lipoic acid biosynthesis defects. J Inherit Metab Dis. 2014; 37(4): 553–63.

[119] Xiong C, Ling H, Hao Q, Zhou X. Cuproptosis: p53-regulated metabolic cell death? Cell Death Differ. 2023; 30(4): 876–84.

[120] Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023; 22(1): 46.

[121] Zhao Q, Qi T. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression. Front Oncol. 2023; 13: 1117164.

[122] Chen CH, Chou YT, Yang YW, Lo KY. High-dose copper activates p53-independent apoptosis through the induction of nucleolar stress in human cell lines. Apoptosis. 2021; 26(11-12): 612–27.

[123] Zhang S, Huang Q, Ji T, Li Q, Hu C. Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy. Biomark Res. 2024; 12(1): 130.

[124] Pan C, Ji Z, Wang Q, Zhang Z, Wang Z, Li C, et al. Cuproptosis: Mechanisms, biological significance, and advances in disease treatment-A systematic review. CNS Neurosci Ther. 2024; 30(9): e70039.

[125] Luo J, Wang J, Huang J. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep. 2021; 41(10): BSR20211103.

[126] Qin Y, Liu Y, Xiang X, Long X, Chen Z, Huang X, et al. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis. Mol Cancer. 2023; 22(1): 59.

[127] Xande JG, Dias AP, Tamura RE, Cruz MC, Brito B, Ferreira RA, et al. Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo. Gene Ther. 2020; 27(1-2): 51–61.

[128] Dreishpoon MB, Bick NR, Petrova B, Warui DM, Cameron A, Booker SJ, et al. FDX1 regulates cellular protein lipoylation through direct binding to LIAS. J Biol Chem. 2023; 299(9): 105046.

[129] Xu J, Hu Z, Cao H, Zhang H, Luo P, Zhang J, et al. Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma. Front Immunol. 2022; 13: 981764.

[130] Wang T, Liu Y, Li Q, Luo Y, Liu D, Li B. Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma. Front Immunol. 2022; 13: 999823.

[131] Lutsenko S, Roy S, Tsvetkov P. Mammalian copper homeostasis: physiological roles and molecular mechanisms. Physiol Rev. 2025; 105(1): 441–91.

[132] Liu X, Luo B, Wu X, Tang Z. Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer. Biochim Biophys Acta Rev Cancer. 2023; 1878(6): 189013.

[133] Baharvand M, Manifar S, Akkafan R, Mortazavi H, Sabour S. Serum levels of ferritin, copper, and zinc in patients with oral cancer. Biomed J. 2014; 37(5): 331–6.

[134] Mazdak H, Yazdekhasti F, Movahedian A, Mirkheshti N, Shafieian M. The comparative study of serum iron, copper, and zinc levels between bladder cancer patients and a control group. Int Urol Nephrol. 2010; 42(1): 89–93.

[135] Yaman M, Kaya G, Simsek M. Comparison of trace element concentrations in cancerous and noncancerous human endometrial and ovary tissues. Int J Gynecol Cancer. 2007; 17(1): 220–8.

[136] Margalioth EJ, Schenker JG, Chevion M. Copper and zinc levels in normal and malignant tissues. Cancer. 1983; 52(5): 868–72.

[137] Saleh SAK, Adly HM, Abdelkhaliq AA, Nassir AM. Serum Levels of Selenium, Zinc, Copper, Manganese, and Iron in Prostate Cancer Patients. Curr Urol. 2020; 14(1): 44–9.

[138] Nayak SB, Bhat VR, Upadhyay D, Udupa SL. Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol. 2003; 47(1): 108–10.

[139] Pavithra V, Sathisha TG, Kasturi K, Mallika DS, Amos SJ, Ragunatha S. Serum levels of metal ions in female patients with breast cancer. J Clin Diagn Res. 2015; 9(1): BC25–c7.

[140] Feng JF, Lu L, Zeng P, Yang YH, Luo J, Yang YW, et al. Serum total oxidant/antioxidant status and trace element levels in breast cancer patients. Int J Clin Oncol. 2012; 17(6): 575–83.

[141] Yaman M, Kaya G, Yekeler H. Distribution of trace metal concentrations in paired cancerous and non-cancerous human stomach tissues. World J Gastroenterol. 2007; 13(4): 612–8.

[142] Lener MR, Scott RJ, Wiechowska-Kozłowska A, Serrano-Fernández P, Baszuk P, Jaworska-Bieniek K, et al. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat. 2016; 48(3): 1056–64.

[143] Basu S, Singh MK, Singh TB, Bhartiya SK, Singh SP, Shukla VK. Heavy and trace metals in carcinoma of the gallbladder. World J Surg. 2013; 37(11): 2641–6.

[144] Wang W, Wang X, Luo J, Chen X, Ma K, He H, et al. Serum Copper Level and the Copper-to-Zinc Ratio Could Be Useful in the Prediction of Lung Cancer and Its Prognosis: A Case-Control Study in Northeast China. Nutr Cancer. 2021; 73(10): 1908–15.

[145] Kosova F, Cetin B, Akinci M, Aslan S, Seki A, Pirhan Y, et al. Serum copper levels in benign and malignant thyroid diseases. Bratisl Lek Listy. 2012; 113(12): 718–20.

[146] Shen F, Cai WS, Li JL, Feng Z, Cao J, Xu B. The Association Between Serum Levels of Selenium, Copper, and Magnesium with Thyroid Cancer: a Meta-analysis. Biol Trace Elem Res. 2015; 167(2): 225–35.

[147] Moison C, Gracias D, Schmitt J, Girard S, Spinella JF, Fortier S, et al. SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia. Sci Adv. 2024; 10(12): eadl4018.

[148] Liao Y, Zhao J, Bulek K, Tang F, Chen X, Cai G, et al. Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis. Nat Commun. 2020; 11(1): 900.

[149] Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021; 31(2): 107–25.

[150] Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021; 17(9): 2054–81.

[151] Xue Q, Yan D, Chen X, Li X, Kang R, Klionsky DJ, et al. Copper-dependent autophagic degradation of GPX4 drives ferroptosis. Autophagy. 2023; 19(7): 1982–96.

[152] Yang L, Chen X, Yang Q, Chen J, Huang Q, Yao L, et al. Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells. Front Oncol. 2020; 10: 949.

[153] Yang Z, Su W, Wei X, Qu S, Zhao D, Zhou J, et al. HIF-1α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1. Cell Rep. 2023; 42(8): 112945.

[154] Yang M, Wu X, Hu J, Wang Y, Wang Y, Zhang L, et al. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. J Hepatol. 2022; 76(5): 1138–50.

[155] Zhou H, Liu Z, Zhang Z, Pandey NK, Amador E, Nguyen W, et al. Copper-cysteamine nanoparticle-mediated microwave dynamic therapy improves cancer treatment with induction of ferroptosis. Bioact Mater. 2023; 24: 322–30.

[156] Chen H, Wang Y, Luo J, Kang M, Hou J, Tang R, et al. Autophagy and apoptosis mediated nano-copper-induced testicular damage. Ecotoxicol Environ Saf. 2022; 229: 113039.

[157] Kawakami M, Inagawa R, Hosokawa T, Saito T, Kurasaki M. Mechanism of apoptosis induced by copper in PC12 cells. Food Chem Toxicol. 2008; 46(6): 2157–64.

[158] Chen F, Tang H, Cai X, Lin J, Xiang L, Kang R, et al. Targeting paraptosis in cancer: opportunities and challenges. Cancer Gene Ther. 2024; 31(3): 349–63.

[159] Lee D, Kim IY, Saha S, Choi KS. Paraptosis in the anti-cancer arsenal of natural products. Pharmacol Ther. 2016; 162: 120–33.

[160] Guo Z, Gao X, Lu J, Li Y, Jin Z, Fahad A, et al. Apoptosis and Paraptosis Induced by Disulfiram-Loaded Ca(2+)/Cu(2+) Dual-Ions Nano Trap for Breast Cancer Treatment. ACS Nano. 2024; 18(9): 6975–89.

[161] Paniagua Soriano G, De Bruin G, Overkleeft HS, Florea BI. Toward understanding induction of oxidative stress and apoptosis by proteasome inhibitors. Antioxid Redox Signal. 2014; 21(17): 2419–43.

[162] Wójcik C. Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med. 2002; 6(1): 25–48.

[163] Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015; 517(7534): 311–20.

[164] Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022; 7(1): 196.

[165] Wang R, Hou L, Lu H, Zhang Y, Guo T, Zhou B, et al. Unveiling the interplay of MAPK/NF-κB/MLKL axis in brain health: Omega-3 as a promising candidates against copper neurotoxicity. J Environ Manage. 2024; 370: 122791.

[166] Yang F, Zhang G, An N, Dai Q, Cho W, Shang H, et al. Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications. Semin Cancer Biol. 2024; 106–107: 106-22.

[167] Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021; 6(1): 128.

[168] Wei X, Xie F, Zhou X, Wu Y, Yan H, Liu T, et al. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol. 2022; 19(9): 971–92.

[169] Liao J, Yang F, Tang Z, Yu W, Han Q, Hu L, et al. Inhibition of Caspase-1-dependent pyroptosis attenuates copper-induced apoptosis in chicken hepatocytes. Ecotoxicol Environ Saf. 2019; 174: 110–9.

[170] Liao J, Hu Z, Li Q, Li H, Chen W, Huo H, et al. Endoplasmic Reticulum Stress Contributes to Copper-Induced Pyroptosis via Regulating the IRE1α-XBP1 Pathway in Pig Jejunal Epithelial Cells. J Agric Food Chem. 2022; 70(4): 1293–303.

[171] Gerstberger S, Jiang Q, Ganesh K.. Metastasis. Cell. 2023; 186(8): 1564–79.

[172] Spangle JM, Roberts TM. Epigenetic regulation of RTK signaling. J Mol Med (Berl). 2017; 95(8): 791–8.

[173] He F, Chang C, Liu B, Li Z, Li H, Cai N, et al. Copper (II) Ions Activate Ligand-Independent Receptor Tyrosine Kinase (RTK) Signaling Pathway. Biomed Res Int. 2019; 2019: 4158415.

[174] Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005; 6(5): 322–7.

[175] Park JI. MAPK-ERK Pathway. Int J Mol Sci. 2023; 24(11): 9666.

[176] Turski ML, Brady DC, Kim HJ, Kim BE, Nose Y, Counter CM, et al. A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol. 2012; 32(7): 1284–95.

[177] Baldari S, Di Rocco G, Heffern MC, Su TA, Chang CJ, Toietta G. Effects of Copper Chelation on BRAF(V600E) Positive Colon Carcinoma Cells. Cancers (Basel). 2019; 11(5): 659.

[178] Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014; 509(7501): 492–6.

[179] Nowell CS, Radtke F. Notch as a tumour suppressor. Nat Rev Cancer. 2017; 17(3): 145–59.

[180] Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022; 7(1): 95.

[181] Parr-Sturgess CA, Tinker CL, Hart CA, Brown MD, Clarke NW, Parkin ET. Copper modulates zinc metalloproteinase-dependent ectodomain shedding of key signaling and adhesion proteins and promotes the invasion of prostate cancer epithelial cells. Mol Cancer Res. 2012; 10(10): 1282–93.

[182] Nusse R, Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017; 169(6): 985–99.

[183] Rim EY, Clevers H, Nusse R. The Wnt Pathway: From Signaling Mechanisms to Synthetic Modulators. Annu Rev Biochem. 2022; 91: 571–98.

[184] Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016; 99: 141–9.

[185] Guo J, Zhao Y, Sui H, Liu L, Liu F, Yang L, et al. USP21-mediated G3BP1 stabilization accelerates proliferation and metastasis of esophageal squamous cell carcinoma via activating Wnt/β-Catenin signaling. Oncogenesis. 2024; 13(1): 23.

[186] Ling W, Li S, Zhu Y, Wang X, Jiang D, Kang B. Inducers of Autophagy and Cell Death: Focus on Copper Metabolism. Ecotoxicol Environ Saf. 2025; 290: 117725.

[187] Li T, Wang G. Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities. Int J Mol Sci. 2014; 15(10): 18856–91.

[188] Ostrakhovitch EA, Lordnejad MR, Schliess F, Sies H, Klotz LO. Copper ions strongly activate the phosphoinositide-3-kinase/Akt pathway independent of the generation of reactive oxygen species. Arch Biochem Biophys. 2002; 397(2): 232–9.

[189] Guo J, Cheng J, Zheng N, Zhang X, Dai X, Zhang L, et al. Copper Promotes Tumorigenesis by Activating the PDK1-AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner. Adv Sci (Weinh). 2021; 8(18): e2004303.

[190] Walter PL, Kampkötter A, Eckers A, Barthel A, Schmoll D, Sies H, et al. Modulation of FoxO signaling in human hepatoma cells by exposure to copper or zinc ions. Arch Biochem Biophys. 2006; 454(2): 107–13.

[191] Ma J, Xie Y, Zhou Y, Wang D, Cao L, Zhou M, et al. Urinary copper, systemic inflammation, and blood lipid profiles: Wuhan-Zhuhai cohort study. Environ Pollut. 2020; 267: 115647.

[192] Krishnamoorthy L, Cotruvo JA,, Chan J, Kaluarachchi H, Muchenditsi A, Pendyala VS, et al. Copper regulates cyclic-AMP-dependent lipolysis. Nat Chem Biol. 2016; 12(8): 586–92.

[193] Du C, Guan X, Liu Y, Xu Z, Du X, Li B, et al. Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc. Cancer Chemother Pharmacol. 2022; 89(4): 451–8.

[194] McAuslan BR, Reilly W. Endothelial cell phagokinesis in response to specific metal ions. Exp Cell Res. 1980; 130(1): 147–57.

[195] Narayanan G, R BS, Vuyyuru H, Muthuvel B, Konerirajapuram Natrajan S. CTR1 silencing inhibits angiogenesis by limiting copper entry into endothelial cells. PLoS One. 2013; 8(9): e71982.

[196] Mandinov L, Mandinova A, Kyurkchiev S, Kyurkchiev D, Kehayov I, Kolev V, et al. Copper chelation represses the vascular response to injury. Proc Natl Acad Sci U S A. 2003; 100(11): 6700–5.

[197] Prudovsky I, Bagala C, Tarantini F, Mandinova A, Soldi R, Bellum S, et al. The intracellular translocation of the components of the fibroblast growth factor 1 release complex precedes their assembly prior to export. J Cell Biol. 2002; 158(2): 201–8.

[198] Badet J, Soncin F, Guitton JD, Lamare O, Cartwright T, Barritault D. Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc Natl Acad Sci U S A. 1989; 86(21): 8427–31.

[199] Martin F, Linden T, Katschinski DM, Oehme F, Flamme I, Mukhopadhyay CK, et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood. 2005; 105(12): 4613–9.

[200] Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. 2010; 18(5): 511–8.

[201] Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015; 13(11): 2395–402.

[202] Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Nat Rev Dis Primers. 2018; 4(1): 21.

[203] Turnlund JR, Keyes WR, Kim SK, Domek JM. Long-term high copper intake: effects on copper absorption, retention, and homeostasis in men. Am J Clin Nutr. 2005; 81(4): 822–8.

[204] Harvey LJ, Ashton K, Hooper L, Casgrain A, Fairweather-Tait SJ. Methods of assessment of copper status in humans: a systematic review. Am J Clin Nutr. 2009; 89(6): 2009s–24s.

[205] Li H, Wang J, Wu C, Wang L, Chen ZS, Cui W. The combination of disulfiram and copper for cancer treatment. Drug Discov Today. 2020; 25(6): 1099–108.

[206] McMahon A, Chen W, Li F. Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy. J Control Release. 2020; 319: 352–9.

[207] Jiao Y, Hannafon BN, Ding WQ. Disulfiram's Anticancer Activity: Evidence and Mechanisms. Anticancer Agents Med Chem. 2016; 16(11): 1378–84.

[208] Li Y, Chen F, Chen J, Chan S, He Y, Liu W, et al. Disulfiram/Copper Induces Antitumor Activity against Both Nasopharyngeal Cancer Cells and Cancer-Associated Fibroblasts through ROS/MAPK and Ferroptosis Pathways. Cancers (Basel). 2020; 12(1): 138.

[209] Ren X, Li Y, Zhou Y, Hu W, Yang C, Jing Q, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol. 2021; 46: 102122.

[210] Wu X, Xue X, Wang L, Wang W, Han J, Sun X, et al. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer. Eur J Pharmacol. 2018; 827: 1–12.

[211] Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL,. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther. 2002; 1(3): 197–204.

[212] Zhao L, Wang X, Lou H, Jiang M, Wu X, Qin J, et al. Buffet-style Cu(II) for enhance disulfiram-based cancer therapy. J Colloid Interface Sci. 2022; 624: 734–46.

[213] Zheng P, Zhou C, Lu L, Liu B, Ding Y. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J Exp Clin Cancer Res. 2022; 41(1): 271.

[214] Nagai M, Vo NH, Shin Ogawa L, Chimmanamada D, Inoue T, Chu J, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med. 2012; 52(10): 2142–50.

[215] Buccarelli M, D'Alessandris QG, Matarrese P, Mollinari C, Signore M, Cappannini A, et al. Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. J Exp Clin Cancer Res. 2021; 40(1): 228.

[216] Cierlitza M, Chauvistré H, Bogeski I, Zhang X, Hauschild A, Herlyn M, et al. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Exp Dermatol. 2015; 24(2): 155–7.

[217] Sciegienka SJ, Solst SR, Falls KC, Schoenfeld JD, Klinger AR, Ross NL, et al. D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H(2)O(2)-mediated oxidative stress. Free Radic Biol Med. 2017; 108: 354–61.

[218] Ji HB, Kim CR, Min CH, Han JH, Kim SN, Lee C, et al. Fe-containing metal-organic framework with D-penicillamine for cancer-specific hydrogen peroxide generation and enhanced chemodynamic therapy. Bioeng Transl Med. 2023; 8(3): e10477.

[219] Chen SJ, Kuo CC, Pan HY, Tsou TC, Yeh SC, Chang JY. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Biochem Pharmacol. 2015; 95(1): 28–37.

[220] Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, et al. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014; 32(3): 465–72.

[221] Huang YF, Kuo MT, Liu YS, Cheng YM, Wu PY, Chou CY. A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. Front Oncol. 2019; 9: 437.

[222] Schimmer AD. Clioquinol - a novel copper-dependent and independent proteasome inhibitor. Curr Cancer Drug Targets. 2011; 11(3): 325–31.

[223] Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res. 2005; 65(8): 3389–95.

[224] Xiao C, Wang X, Li S, Zhang Z, Li J, Deng Q, et al. A cuproptosis-based nanomedicine suppresses triple negative breast cancers by regulating tumor microenvironment and eliminating cancer stem cells. Biomaterials. 2025; 313: 122763.

[225] Veeranarayanan S, Mohamed MS, Poulose AC, Rinya M, Sakamoto Y, Maekawa T, et al. Photodynamic therapy at ultra-low NIR laser power and X-Ray imaging using Cu(3)BiS(3) nanocrystals. Theranostics. 2018; 8(19): 5231–45.

[226] Guo B, Yang F, Zhang L, Zhao Q, Wang W, Yin L, et al. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD-L1 for Enhanced Cancer Immunotherapy. Adv Mater. 2023; 35(22): e2212267.

[227] Wang Q, Huang CH, Wibowo FS, Amin R, Shen J, Li F, et al. Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells. ACS Appl Mater Interfaces. 2024; 16(11): 13509–24.

[228] Medici V, Sturniolo GC. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications. IDrugs. 2008; 11(8): 592–606.

[229] Wang J, Luo C, Shan C, You Q, Lu J, Elf S, et al. Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. Nat Chem. 2015; 7(12): 968–79.

[230] Kim KK, Abelman S, Yano N, Ribeiro JR, Singh RK, Tipping M, et al. Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells. Sci Rep. 2015; 5: 14296.

[231] Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther. 2007; 6(3): 1039–45.

[232] Yang Y, Tang J, Zhang M, Gu Z, Song H, Yang Y, et al. Responsively Aggregatable Sub-6 nm Nanochelators Induce Simultaneous Antiangiogenesis and Vascular Obstruction for Enhanced Tumor Vasculature Targeted Therapy. Nano Lett. 2019; 19(11): 7750–9.

[233] Baldari S, Di Rocco G, Toietta G. Current Biomedical Use of Copper Chelation Therapy. Int J Mol Sci. 2020; 21(3): 1069.

[234] Zhang X, Jiang Q, Su Y, Bu L, Sun Z, Wu X, et al. AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy. Br J Cancer. 2023; 128(8): 1452–65.

[235] Voli F, Valli E, Lerra L, Kimpton K, Saletta F, Giorgi FM, et al. Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. Cancer Res. 2020; 80(19): 4129–44.

[236] Kimoto E, Tanaka H, Gyotoku J, Morishige F, Pauling L. Enhancement of antitumor activity of ascorbate against Ehrlich ascites tumor cells by the copper:glycylglycylhistidine complex. Cancer Res. 1983; 43(2): 824–8.

[237] Sun T, Zhang G, Guo Z, Chen Q, Zhang Y, Chu Y, et al. Co-delivery of Cu(I) chelator and chemotherapeutics as a new strategy for tumor theranostic. J Control Release. 2020; 321: 483–96.

[238] O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013; 31(9): 1211–8.

[239] Boodram JN, McGregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. Angew Chem Int Ed Engl. 2016; 55(8): 2845–50.

[240] Jiang Y, Huo Z, Qi X, Zuo T, Wu Z. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes. Nanomedicine (Lond). 2022; 17(5): 303–24.

[241] Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, Rembach A, et al. Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. J Alzheimers Dis. 2014; 38(4): 809–22.

[242] Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, Chopra V, et al. Mechanisms of copper ion mediated Huntington's disease progression. PLoS One. 2007; 2(3): e334.

[243] Pamp K, Bramey T, Kirsch M, De Groot H, Petrat F. NAD(H) enhances the Cu(II)-mediated inactivation of lactate dehydrogenase by increasing the accessibility of sulfhydryl groups. Free Radic Res. 2005; 39(1): 31–40.

[244] Ford ES. Serum copper concentration and coronary heart disease among US adults. Am J Epidemiol. 2000; 151(12): 1182–8.

[245] Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol. 2004; 24(5): 949–54.

[246] Völker W, Dorszewski A, Unruh V, Robenek H, Breithardt G, Buddecke E. Copper-induced inflammatory reactions of rat carotid arteries mimic restenosis/arteriosclerosis-like neointima formation. Atherosclerosis. 1997; 130(1-2): 29–36.

[247] Werlenius K, Kinhult S, Solheim TS, Magelssen H, Löfgren D, Mudaisi M, et al. Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(3): e234149.

[248] Huang J, Campian JL, DeWees TA, Skrott Z, Mistrik M, Johanns TM, et al. A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys. 2024; 120(3): 738–49.

[249] O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009; 27(32): 5452–8.

[250] Berkenblit A, Eder JP,, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007; 13(2 Pt 1): 584–90.

[251] Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, et al. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018; 151(3): 422–7.

[252] Grassi I, Nanni C, Cicoria G, Blasi C, Bunkheila F, Lopci E, et al. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study. Clin Nucl Med. 2014; 39(1): e59–63.

[253] Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012; 53(8): 1207–15.

[254] Bailey DL, Willowson KP, Harris M, Biggin C, Aslani A, Lengkeek NA, et al. (64)Cu Treatment Planning and (67)Cu Therapy with Radiolabeled [(64)Cu/(67)Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry. J Nucl Med. 2023; 64(5): 704–10.

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.